Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Music lecturer’s innovative app is a first in South Africa
2014-07-24

Dr Frelét de Villiers, lecturer at the Odeion School of Music (OSM) at the University of the Free State (UFS), is in the process of developing an innovative interactive mobile music application – Notes&Fun.

Notes&Fun is being designed to assist aspirant pianists. It will support beginners with notation and rhythmic patterns.

The app will display single notes, phrases or rhythmical patterns on the phone or tablet and then apply the built-in microphone to measure the frequency of the notes played on the piano itself. It will indicate whether you’ve played correctly, or if you have made a mistake, the correct note will be displayed. Notes&Fun consists of multiple levels, each with a practise and test mode that gradually increases in difficulty and complexity. As opposed to existing apps, Notes&Fun is conceptualised with immediate pitch detection and is applied with a real (acoustic) piano.

For the pilot phase of this initiative, the developing company Maxxor in Cape Town will create a demo app which can be downloaded for testing purposes and general feedback. Once the developing company and innovator are satisfied with the first phase, the product will be marketed vigorously on social media. The initial app will be free, but subsequent levels will need to be purchased. The developers will start a Facebook page where users of the app can add their latest scores and compete with other users. Initially the app will only be available on the Google Play Store due to the fact that more people own Android devices than Apple products. Once the product has proven to be financially viable, the developers will adapt it for the Mac App Store as well.

“The beauty of this app is that music has a universal language, so it can be marketed internationally and I am privileged to have the institutional support from the UFS Technology Unit regarding the judicial process and developing process of the product,” Dr De Villiers said.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept